| Document Date: 2013-06-18 04:33:09
Open Document File Size: 714,20 KBShare Result on Facebook
Company Nycomed / Emerging / Takeda Group / results/ Takeda Pharmaceutical Company Limited / Pantoprazole / Takeda Pharmaceutical Company Limited Stock exchange / URL Pharma Inc. / / Continent Asia / North America / Europe / / Country Japan / United States / / Event Dividend Issuance / M&A / Reorganization / / IndustryTerm treatment of prostate cancer / cancer treatment / hypertension treatment / treatment of hypertension / vitamin-containing products / diabetes treatment / / MedicalCondition multiple myeloma treatment Increase / iron deficiency / IBD / peptic ulcer / hypertension / cancer / hyperlipidemia / generic name / chronic obstructive pulmonary disease / reflux disease / diabetes / endometriosis / non-metastatic osteosarcoma / systemic anaplastic large cell lymphoma / CD30 positive Hodgkin lymphoma / chronic gout / prostate cancer / gastroesophageal reflux disease / breast cancer / multiple myeloma treatment / / Organization European Medicines Agency / U.S. Food and Drug Administration / / Person Respiratory / Christopher Hohman / Yasuchika Hasegawa / / / Position Senior Vice President / Corporate Communications Department Scheduled date / Representative / General / President & CEO / / Product Pioglitazone / Vectibix / VELCADE / Actoplus met / Lansoprazole / chlorthalidone / Actos / Alinamin tablets / Pantoprazole / / URL http /
SocialTag |
SUMMARY OF FINANCIAL STATEMENTS [Japan GAAP] (CONSOLIDATED) Financial Results for the Fiscal Year Ended March 31, 2013 May 9, 2013 Takeda Pharmaceutical Company Limited